Table 4 Prognostic factors in 229 patients with IPF treated with antifibrotic therapy by univariate and multivariate Cox-proportion analyses.

From: Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis

Predictor

HR

95% CI

p-value

 

HR

95% CI

p-value

Univariate analysis

Multivariate analysis 1

Age, year

1.022

0.995–1.051

0.1169

Age, year

0.998

0.970–1.028

0.8877

Gender, male

1.262

0.767–1.981

0.3324

Gender, male

1.243

0.734–2.241

0.4428

History of AE, yes

2.277

1.314–3.704

0.0017

History of AE, yes

1.320

0.710–2.313

0.3541

Pirfenidone

1.039

0.703–1.566

0.8519

BMI, kg/m2 (continuous variable)

0.929

0.869–1.077

0.0273

BMI, kg/m2 (continuous variable)

0.896

0.847–0.947

0.0001

FVC, %

0.984

0.971–0.997

0.0199

FVC, %

0.967

0.956–0.978

 < 0.0001

DLCO, %

0.983

0.970–0.996

0.0119

FEV1, %

0.986

0.975–0.996

0.0093

LTOT, yes

1.692

1.104–2.562

0.0141

FEV1/FVC, %

1.065

1.040–1.091

 < 0.0001

Multivariate analysis 2

DLCO, %

0.974

0.962–0.986

 < 0.0001

GAP index, stage

2.161

1.615–2.899

 < 0.0001

TP, g/dl

0.960

0.733–1.277

0.7720

BMI, kg/m2 (continuous variable)

0.931

0.882–0.983

0.0093

Alb, g/dl

0.572

0.376–0.881

0.0094

History of AE, yes

1.354

0.758–2.289

0.2799

KL-6, U/ml

1.000

1.000–1.001

 < 0.0001

LTOT, yes

1.706

1.138–2.533

0.0088

SP-D, ng/ml

1.001

1.000–1.002

0.0760

Multivariate analysis 3

LTOT, yes

2.660

1.847–3.810

 < 0.0001

GAP index: gender

1.303

0.801–2.214

0.3046

GAP index, stage

2.637

1.993–3.491

 < 0.0001

GAP index: age

1.021

0.757–1.426

0.8990

GAP index, score

1.641

1.437–1.870

 < 0.0001

GAP index: FVC%

1.666

1.201–2.321

0.0024

GAP index: age

1.226

0.917–1.701

0.1945

GAP index: DLCO%

1.495

1.170–1.907

0.0012

GAP index: FVC%

2.549

1.913–3.402

 < 0.0001

BMI, kg/m2 (continuous variable)

0.930

0.879–0.983

0.0104

GAP index: DLCO%

1.969

1.591–2.419

 < 0.0001

History of AE, yes

1.414

0.785–2.414

0.2242

BMI < 24.0 kg/m2 (categorical variable)

2.110

1.440–3.157

0.0002

LTOT, yes

1.519

0.983–2.317

0.0556

  1. AE acute exacerbation, BMI body mass index, FVC forced vital capacity, FEV1.0 forced expiratory volume in 1.0 s, DLCO diffuse capacity of the lung for carbon monoxide, KL-6 Krebs von den Lunge-6, SP-D surfactant protein-D, LTOT long-term oxygen therapy, GAP Gender-Age-Physiology.
Back to article page